{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T05:34:51Z","timestamp":1792128891870,"version":"4.4.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jval.2022.12.005","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T20:31:27Z","timestamp":1671136287000},"page":"823-832","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cost-Effectiveness of Nadofaragene Firadenovec and Pembrolizumab in Bacillus Calmette-Gu\u00e9rin Immunotherapy Unresponsive Non\u2013Muscle Invasive Bladder Cancer"],"prefix":"10.1016","volume":"26","author":[{"given":"Mrinmayee","family":"Joshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Atlas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Beinfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard H.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Rind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Touchette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2022.12.005_bib1","unstructured":"Cancer Stat Facts: Bladder Cancer. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html. Accessed February 20, 2022."},{"key":"10.1016\/j.jval.2022.12.005_bib2","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2147\/CEOR.S274951","article-title":"Humanistic and economic burden of non-muscle invasive bladder cancer: results of two systematic literature reviews","volume":"12","author":"Lee","year":"2020","journal-title":"Clinicoecon Outcomes Res"},{"issue":"11","key":"10.1016\/j.jval.2022.12.005_bib3","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s40273-014-0194-2","article-title":"The health economics of bladder cancer: an updated review of the published literature","volume":"32","author":"Yeung","year":"2014","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.jval.2022.12.005_bib4","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/MOU.0000000000000078","article-title":"The burden of bladder cancer care: direct and indirect costs","volume":"24","author":"Mossanen","year":"2014","journal-title":"Curr Opin Urol"},{"issue":"6 suppl 1","key":"10.1016\/j.jval.2022.12.005_bib6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.urology.2005.07.062","article-title":"Bladder cancer: epidemiology, staging and grading, and diagnosis","volume":"66","author":"Kirkali","year":"2005","journal-title":"Urology"},{"issue":"6 suppl 4","key":"10.1016\/j.jval.2022.12.005_bib7","first-page":"S199","article-title":"The management of BCG failure in non-muscle-invasive bladder cancer: an update","volume":"3","author":"Zlotta","year":"2009","journal-title":"Can Urol Assoc J"},{"issue":"3","key":"10.1016\/j.jval.2022.12.005_bib8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.eururo.2020.02.012","article-title":"Systematic review of the therapeutic efficacy of bladder-preserving treatments for non-muscle-invasive bladder cancer following intravesical bacillus Calmette-Gu\u00e9rin","volume":"78","author":"Li","year":"2020","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.jval.2022.12.005_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.3800","article-title":"Estimated costs and long-term outcomes of patients with high-risk non-muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin in the Veterans Affairs health system","volume":"4","author":"Williams","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.jval.2022.12.005_bib10","first-page":"1021","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J\u00a0Urol"},{"issue":"3","key":"10.1016\/j.jval.2022.12.005_bib11","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2020.0011","article-title":"Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Flaig","year":"2020","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.jval.2022.12.005_bib12","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/323157","article-title":"Complications of radical cystectomy and orthotopic reconstruction","volume":"2015","author":"Tan","year":"2015","journal-title":"Adv Urol"},{"issue":"3","key":"10.1016\/j.jval.2022.12.005_bib13","first-page":"669","article-title":"Health related quality of life following radical cystectomy: comparative analysis from the Medicare health outcomes survey","volume":"199","author":"Winters","year":"2018","journal-title":"J\u00a0Urol"},{"issue":"15","key":"10.1016\/j.jval.2022.12.005_bib14","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2002.02.066","article-title":"Phase I trial of intravesical gemcitabine in bacillus Calmette-Gu\u00e9rin-refractory transitional-cell carcinoma of the bladder","volume":"20","author":"Dalbagni","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.jval.2022.12.005_bib15","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.urology.2005.04.062","article-title":"Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a phase II prospective multicenter study","volume":"66","author":"Bartoletti","year":"2005","journal-title":"Urology"},{"issue":"18","key":"10.1016\/j.jval.2022.12.005_bib16","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1200\/JCO.2005.05.2720","article-title":"Phase II trial of intravesical gemcitabine in bacille Calmette-Gu\u00e9rin-refractory transitional cell carcinoma of the bladder","volume":"24","author":"Dalbagni","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.jval.2022.12.005_bib17","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/sj.bjc.6604074","article-title":"Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study","volume":"97","author":"Gunelli","year":"2007","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.jval.2022.12.005_bib18","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/CAD.0b013e3283324d83","article-title":"Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial","volume":"21","author":"Perdon\u00e0","year":"2010","journal-title":"Anticancer Drugs"},{"issue":"4","key":"10.1016\/j.jval.2022.12.005_bib19","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","article-title":"Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance","volume":"28","author":"Addeo","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.jval.2022.12.005_bib20","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/cncr.24914","article-title":"Gemcitabine versus bacille Calmette-Gu\u00e9rin after initial bacille Calmette-Gu\u00e9rin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial","volume":"116","author":"Di Lorenzo","year":"2010","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.jval.2022.12.005_bib21","first-page":"1200","article-title":"SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Gu\u00e9rin","volume":"190","author":"Skinner","year":"2013","journal-title":"J\u00a0Urol"},{"issue":"5","key":"10.1016\/j.jval.2022.12.005_bib22","first-page":"1686","article-title":"Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Gu\u00e9rin treatment failure","volume":"190","author":"Sternberg","year":"2013","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.jval.2022.12.005_bib23","doi-asserted-by":"crossref","first-page":"95","DOI":"10.7257\/1053-816X.2014.34.2.95","article-title":"Initial experience of intravesical gemcitabine for patients with high-risk superficial transitional cell carcinoma of the bladder following BCG failure","volume":"34","author":"Allchorne","year":"2014","journal-title":"Urol Nurs"},{"issue":"1","key":"10.1016\/j.jval.2022.12.005_bib24","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BLC-150008","article-title":"Sequential intravesical gemcitabine and docetaxel for the salvage treatment of non-muscle invasive bladder cancer","volume":"1","author":"Steinberg","year":"2015","journal-title":"Bladder Cancer"},{"issue":"4","key":"10.1016\/j.jval.2022.12.005_bib25","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/BLC-170126","article-title":"Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer","volume":"3","author":"Milbar","year":"2017","journal-title":"Bladder Cancer"},{"issue":"2","key":"10.1016\/j.jval.2022.12.005_bib26","doi-asserted-by":"crossref","first-page":"40.e17","DOI":"10.1016\/j.urolonc.2019.07.022","article-title":"An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine\/docetaxel for nonmuscle-invasive bladder cancer","volume":"38","author":"Daniels","year":"2020","journal-title":"Urol Oncol"},{"issue":"5","key":"10.1016\/j.jval.2022.12.005_bib27","first-page":"902","article-title":"Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer","volume":"203","author":"Steinberg","year":"2020","journal-title":"J\u00a0Urol"},{"issue":"3","key":"10.1016\/j.jval.2022.12.005_bib28","first-page":"761","article-title":"Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The valrubicin study group [published correction appears in J Urol. 2008;179(1):386]","volume":"163","author":"Steinberg","year":"2000","journal-title":"J\u00a0Urol"},{"issue":"8","key":"10.1016\/j.jval.2022.12.005_bib29","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.urolonc.2012.04.010","article-title":"Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Gu\u00e9rin","volume":"31","author":"Dinney","year":"2013","journal-title":"Urol Oncol"},{"issue":"7","key":"10.1016\/j.jval.2022.12.005_bib30","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study [published correction appears in Lancet Oncol. 2021;22(8):e347]","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jval.2022.12.005_bib31","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jval.2022.12.005_bib32","unstructured":"Atlas S, Touchette D, Beinfeld M, et al. Nadofaragene firadenovec and oportuzumab monatox for BCG-unresponsive, non-muscle invasive bladder cancer: effectiveness and value. Institute for Clinical and Economic Review. https:\/\/icer.org\/wp-content\/uploads\/2020\/08\/ICER_Bladder-Cancer_Final-Report_053122.pdf. Accessed March 20, 2022."},{"issue":"6","key":"10.1016\/j.jval.2022.12.005_bib33","first-page":"797","article-title":"The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer","volume":"27","author":"Beinfeld","year":"2021","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"10","key":"10.1016\/j.jval.2022.12.005_bib35","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1002\/hec.3085","article-title":"The willingness to pay for a quality adjusted life year: a review of the empirical literature","volume":"24","author":"Ryen","year":"2015","journal-title":"Health Econ"},{"issue":"1","key":"10.1016\/j.jval.2022.12.005_bib36","doi-asserted-by":"crossref","DOI":"10.1080\/16549716.2018.1447828","article-title":"On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: a systematic review","volume":"11","author":"Cameron","year":"2018","journal-title":"Glob Health Action"},{"issue":"1","key":"10.1016\/j.jval.2022.12.005_bib37","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1257\/jep.29.1.139","article-title":"Pricing in the market for anticancer drugs","volume":"29","author":"Howard","year":"2015","journal-title":"J\u00a0Econ Perspect"},{"issue":"1","key":"10.1016\/j.jval.2022.12.005_bib38","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.eururo.2018.09.005","volume":"75","author":"Tan","year":"2019","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.jval.2022.12.005_bib39","first-page":"1326","article-title":"Cost-effectiveness analysis of pembrolizumab for bacillus Calmette-Gu\u00e9rin-unresponsive carcinoma in situ of the bladder","volume":"205","author":"Wymer","year":"2021","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.jval.2022.12.005_bib40","first-page":"39","article-title":"Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder. Bladder Photofrin Study Group","volume":"160","author":"Nseyo","year":"1998","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.jval.2022.12.005_bib41","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BLC-160084","article-title":"Efficacy of Mycobacterium phlei cell wall-nucleic acid complex (MCNA) in BCG-unresponsive patients","volume":"3","author":"Li","year":"2017","journal-title":"Bladder Cancer"},{"issue":"5","key":"10.1016\/j.jval.2022.12.005_bib42","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.urolonc.2008.05.004","article-title":"Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): A trial of the Eastern Cooperative Oncology Group","volume":"27","author":"Ignatoff","year":"2009","journal-title":"Urol Oncol"},{"issue":"6","key":"10.1016\/j.jval.2022.12.005_bib43","first-page":"1633","article-title":"Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette-Gu\u00e9rin treatment failure","volume":"192","author":"McKiernan","year":"2014","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.jval.2022.12.005_bib44","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1186\/s12885-018-5134-7","article-title":"ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk \u201cBCG failure\u201d non muscle invasive bladder cancer: 3 years follow-up outcomes","volume":"18","author":"Racioppi","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jval.2022.12.005_bib45","unstructured":"Human Mortality Database. U.S.A. Total population. https:\/\/www.mortality.org\/Country\/Country?cntr=USA. Accessed March 20, 2022."},{"issue":"16","key":"10.1016\/j.jval.2022.12.005_bib46","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","volume":"29","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.jval.2022.12.005_bib47","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/jnci\/djq121","article-title":"Use of radical cystectomy for patients with invasive bladder cancer","volume":"102","author":"Gore","year":"2010","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"21","key":"10.1016\/j.jval.2022.12.005_bib48","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jval.2022.12.005_bib49","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.urology.2020.08.004","article-title":"Contemporary treatment patterns for non-muscle-invasive bladder cancer: has the use of radical cystectomy changed in the BCG shortage era?","volume":"147","author":"Tully","year":"2021","journal-title":"Urology"},{"issue":"6 pt 1","key":"10.1016\/j.jval.2022.12.005_bib50","first-page":"2414","article-title":"Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium","volume":"176","author":"Shariat","year":"2006","journal-title":"J\u00a0Urol"},{"issue":"9","key":"10.1016\/j.jval.2022.12.005_bib51","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1371\/journal.pmed.0040284","article-title":"Optimal management of high-risk T1G3 bladder cancer: a decision analysis","volume":"4","author":"Kulkarni","year":"2007","journal-title":"PLoS Med"},{"issue":"10","key":"10.1016\/j.jval.2022.12.005_bib52","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1007\/s00345-018-2550-x","article-title":"Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories","volume":"37","author":"Mossanen","year":"2019","journal-title":"World J Urol"},{"issue":"3","key":"10.1016\/j.jval.2022.12.005_bib53","doi-asserted-by":"crossref","first-page":"A201","DOI":"10.1016\/j.jval.2015.03.1164","article-title":"Evaluating the cost of treating bladder cancer with and without metastases","volume":"18","author":"Seal","year":"2015","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.jval.2022.12.005_bib54","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.eururo.2014.01.029","article-title":"Propensity-matched comparison of morbidity and costs of open and robot-assisted radical cystectomies: a contemporary population-based analysis in the United States","volume":"66","author":"Leow","year":"2014","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.jval.2022.12.005_bib55","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1080\/03007995.2020.1758927","article-title":"Cost of cystectomy-related complications in patients with bladder cancer in the United States","volume":"36","author":"Malangone-Monaco","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jval.2022.12.005_bib56","unstructured":"Pharmaceutical prices. U.S. Department of Veterans Affairs Office of Procurement, Acquisition and Logistics (OPAL). https:\/\/www.va.gov\/opal\/nac\/fss\/pharmprices.asp. Accessed March 20, 2022."},{"issue":"4","key":"10.1016\/j.jval.2022.12.005_bib59","doi-asserted-by":"crossref","first-page":"e418","DOI":"10.1016\/j.clgc.2019.12.004","article-title":"Effects of bladder cancer on UK healthcare costs and patient health-related quality of life: evidence from the BOXIT trial","volume":"18","author":"Cox","year":"2020","journal-title":"Clin Genitourin Cancer"},{"issue":"9","key":"10.1016\/j.jval.2022.12.005_bib60","first-page":"967","article-title":"The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States","volume":"23","author":"Slater","year":"2020","journal-title":"J\u00a0Med Econ"},{"issue":"1","key":"10.1016\/j.jval.2022.12.005_bib62","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2022.12.005_bib63","doi-asserted-by":"crossref","unstructured":"See WA. Commentary on \u201coutpatient laser ablation of non-muscle-invasive bladder cancer: is it safe, tolerable and cost-effective?\u201d Wong KA, Zisengwe G, Athanasiou T, O\u2019Brien T, Thomas K, The Urology Centre, Guys and St. Thomas\u2019 NHS Foundation Trust. BJU Int. 2013;112(5):561-567.","DOI":"10.1111\/bju.12216"},{"issue":"1","key":"10.1016\/j.jval.2022.12.005_bib64","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1464-410X.2008.08323.x","article-title":"Non-muscle-invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost-effective alternative?","volume":"104","author":"de Bekker-Grob","year":"2009","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.jval.2022.12.005_bib65","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/bju.14502","article-title":"Cost-effectiveness of surveillance schedules in older adults with non-muscle-invasive bladder cancer","volume":"123","author":"Heijnsdijk","year":"2019","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.jval.2022.12.005_bib66","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1186\/s12885-018-4988-z","article-title":"Low-dose bacillus Calmette-Guerin versus full-dose for intermediate and high-risk of non-muscle invasive bladder cancer: a Markov model","volume":"18","author":"Wang","year":"2018","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.jval.2022.12.005_bib67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0202796","article-title":"An early analysis of the cost-effectiveness of a diagnostic classifier for risk stratification of haematuria patients (DCRSHP) compared to flexible cystoscopy in the diagnosis of bladder cancer","volume":"13","author":"Sutton","year":"2018","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jval.2022.12.005_bib68","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.urology.2014.09.041","article-title":"A\u00a0cost-effectiveness analysis of management of low-risk non-muscle-invasive bladder cancer using office-based fulguration","volume":"85","author":"Al Hussein Al Awamlh","year":"2015","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.jval.2022.12.005_bib69","doi-asserted-by":"crossref","first-page":"180.e11","DOI":"10.1016\/j.urolonc.2018.11.016","article-title":"Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced urothelial carcinoma of the bladder in the United States","volume":"37","author":"Criss","year":"2019","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.jval.2022.12.005_bib70","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.eururo.2018.03.006","article-title":"Cost-effectiveness of pembrolizumab in second-line advanced bladder cancer","volume":"74","author":"Sarfaty","year":"2018","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.jval.2022.12.005_bib71","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3233\/BLC-150020","article-title":"Novel simulation model of non-muscle invasive bladder cancer: a platform for a virtual randomized trial of conservative therapy vs. cystectomy in BCG refractory patients","volume":"1","author":"Patel","year":"2015","journal-title":"Bladder Cancer"},{"issue":"3","key":"10.1016\/j.jval.2022.12.005_bib72","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s11136-020-02650-y","article-title":"US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples","volume":"30","author":"Jiang","year":"2021","journal-title":"Qual Life Res"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301522047799?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301522047799?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:32:24Z","timestamp":1761096744000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301522047799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":67,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1098301522047799"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2022.12.005","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Nadofaragene Firadenovec and Pembrolizumab in Bacillus Calmette-Gu\u00e9rin Immunotherapy Unresponsive Non\u2013Muscle Invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2022.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}